Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth


Yan,  Yu
RG Proteomics and Biomarkers, Max Planck Institute of Psychiatry, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Sun, L., Yan, Y., Lv, H., Li, J., Wang, Z., Wang, K., et al. (2022). Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth. CELL CHEMICAL BIOLOGY, 29(3): e6, pp. 373-385. doi:10.1016/j.chembiol.2021.10.006.

Cite as: https://hdl.handle.net/21.11116/0000-000A-6A53-2
Rapamycin is widely recognized as an inhibitor of mTOR, and has been approved for clinical use as an immunosuppressant. Its potencies in anti-cancer, anti-aging, and neurodegenerative diseases are emergingly established. The exploration of other targets of rapamycin will further elucidate its underlying mechanisms of action. In this study, we use a chemical proteomics strategy that has identified STAT3, a transcription factor considered to be undruggable, as a direct functional protein target of rapamycin. Together with other multi-dimensional proteomics data, we show that rapamycin treatment in cell culture significantly inhibits c-Myc-regulated gene expression. Furthermore, we show that rapamycin suppresses tumor growth along with a decreased expression of STAT3 and c-Myc in an in vivo xenograft mouse model for hepatocellular carcinoma. Our data suggest that rapamycin acts directly on STAT3 to decrease its transcription activity, providing important information for the pharmacological and pharmaceutical development of STAT3 inhibitors for cancer therapy.